REVIEW ARTICLECellular immune dysregulation in the pathogenesis of immune thrombocytopeniaWen, Ruitinga,b; Wang, Yufengc; Hong, Yunguangc; Yang, ZhigangdAuthor Information aAcademy of Military Sciences, Academy of Military Medical Sciences bDepartment of Hematopoietic Stem Cell Transplantation, The Fifth Medical Center, Chinese PLA General Hospital (Former 307th Hospital of PLA), Beijing cGuangdong Medical University dDepartment of Hematology and Rheumatology, Affiliated Zhanjiang Central People's Hospital of Guangdong Medical University, Zhanjiang, P.R. China Correspondence to Zhigang Yang, MD, Department of Hematology and Rheumatology, Affiliated Zhanjiang Central People's Hospital of Guangdong Medical University, #236 Yuanzhu Road, Chikan District, Zhanjiang 524045, Guangdong, P.R. China. Tel: +86 759 3152128; e-mail: email@example.com Received 21 September, 2019 Revised 26 November, 2019 Accepted 26 December, 2019 Blood Coagulation & Fibrinolysis: March 2020 - Volume 31 - Issue 2 - p 113-120 doi: 10.1097/MBC.0000000000000891 Buy Metrics Abstract Immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease characterized by immune-mediated increased platelet destruction and decreased platelet production, resulting from immune intolerance to autoantigen. The pathogenesis of ITP remains unclear, although dysfunction of T and B lymphocytes has been shown to be involved in the pathogenesis of ITP. More recently, it is found that dendritic cells, natural killer, and myeloid-derived suppressor cells also play an important role in ITP. Elucidating its pathogenesis is expected to provide novel channels for the targeted therapy of ITP. This article will review the role of different immune cells in ITP. Copyright © 2020 YEAR Wolters Kluwer Health, Inc. All rights reserved.